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transplantation in the Western world. We performed a genome-wide association study for alcohol-related
cirrhosis in individuals of European descent (712 cases and 1,426 controls) with subsequent validation in
two independent European cohorts (1,148 cases and 922 controls). We identified variants in the MBOAT7
(P = 1.03 × 10(-9)) and TM6SF2 (P = 7.89 × 10(-10)) genes as new risk loci and confirmed rs738409 in
PNPLA3 as an important risk locus for alcohol-related cirrhosis (P = 1.54 × 10(-48)) at a genome-wide
level of significance. These three loci have a role in lipid processing, suggesting that lipid turnover is
important in the pathogenesis of alcohol-related cirrhosis.
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LETTER 
Alcohol misuse is the leading cause of cirrhosis and the second most common indication 
for liver transplantation in the Western world1–3. We performed the first genome-wide 
association study for alcohol-related cirrhosis in individuals of European descent (712 
cases and 1,426 controls) with subsequent validation in two independent European 
cohorts (1,148 cases vs. 2,315 controls). Variations in the MBOAT7 (P = 1.03 × 10-09) and 
TM6SF2 (P = 7.89 × 10-10) genes were identified as novel risk loci, while rs738409 in 
PNPLA3 was confirmed as an important risk locus for alcohol-related cirrhosis (P = 1.54 
× 10-48) at a genome-wide level of significance. These three loci play a role in lipid 
processing suggesting that lipid turnover plays an important role in the pathogenesis of 
alcohol-related cirrhosis.  
Hepatic steatosis develops in most heavy alcohol users but more significant liver injury only 
develops with persistent alcohol misuse over time; necroinflammation and progressive 
fibrosis will develop in 10-35 % of individuals while cirrhosis will develop in only 10-15 %4. 
Thus, only a minority of long-term harmful drinkers will develop cirrhosis. Also, twin studies 
are pointing to a significant genetic component to disease susceptibility5,6. 
An early GWAS in non-alcohol-related liver disease (NAFLD) identified the variant, 
rs738409, (148M) in patatin-like phospholipase domain-containing 3 (PNPLA3) as a predictor 
for hepatic fat content7, and a risk factor for disease progression. This same variant has also 
been found to be strongly associated with the risk of developing alcohol-related cirrhosis8,9. 
The functional exploration of PNPLA3 has greatly contributed to our understanding of 
metabolic liver disease10,11. To obtain a more complete assessment of the genetic risk 
structure and to unravel potential new pathways involved in alcohol-related liver disease 
progression, we performed a two-stage GWAS comparing patients with alcohol-related 
cirrhosis (cases) to alcohol misusers without cirrhosis (controls). 
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The first GWAS included 410 Germans with alcohol-related cirrhosis and 1,119 heavy 
drinkers without liver disease from a German psychiatric consortium12. In the second GWAS, 
302 cases and 346 controls from the United Kingdom were genotyped (Table 1). Genotype 
imputation was performed using IMPUTE213 to reference panel 1,000 Genomes Phase 3.  
Meta-analysis was restricted to markers present in both data sets (N = 6,770,426). The 
resulting Manhattan plot is provided in Figure 1. The strongest signal was SNP rs738409 
located in the PNPLA3 gene (P = 1.17 × 10-28), further 102 SNPs of genome-wide 
significance (Pmeta < 5 × 10−8) located at this locus (Supplementary Table 1).  
In addition, a secondary genome-wide meta-analysis adjusted for age, sex, BMI and type 2 
diabetes was performed in 456 cases and 873 controls in whom complete covariate 
information was available (Supplementary Table 2). Genome wide significance was attained 
only at the PNPLA3 locus (Supplementary Table 4). The Manhattan and QQ-plots are 
provided in Supplementary Figures 2 and 3.  
 
As BMI and blood sugar levels are adversely affected by the presence of cirrhosis per se these 
variables may not act as true disease confounders, in this context. In consequence, adjusting 
the analysis for these variables may instead correct for the intended phenotype. Thus, the most 
significant variants of the top 10 loci from the primary, unadjusted meta-analysis were carried 
forward to replication. At stage II the SNPs were validated in independent samples from 
Germany (N = 1,290) and Belgium (N = 779) (Table 1) by fixed-effect model meta-analysis. 
For the definition of an independent locus, a window of at least 500 kb of genomic distance 
was required (Supplementary Table 1). In addition to rs738409 in PNPLA3, disease 
association was replicated for variants: rs626283 in MBOAT7 and rs10401969 in SUGP1 
(Table 2). In the combined analysis of all stage 1-2 samples, both novel replicating SNPs 
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attained genome-wide significant evidence of association (MBOAT7: rs626283 Pcombined = 
1.03×10−9; OR = 1.35 [1.23-1.49] and SUGP1: rs10401969 Pcombined= 7.89 × 10−10; OR = 
1.72 [1.44-2.04]; Table 2) and map to distinct loci.  
To assess the validity of the design choice made for the primary analysis, a post-hoc analysis 
adjusted for age, sex, BMI and type 2 diabetes was performed for replicating variants. The 
three loci remain significant in the adjusted analysis and the odds ratios of the adjusted are 
similar to the unadjusted analysis (Table 3). The top 10 loci from the adjusted GWAS meta-
analysis (Supplementary Table 4) were genotyped in the cohorts outlined in Supplementary 
Table 2. Only PNPLA3 rs738409 variant was replicated with a combined adjusted P-value of 
2.16 × 10-26 (Supplementary Table 3).  
The association of alcohol-related cirrhosis with the three validated loci was assessed for each 
of the three case cohorts (Germans, UK and Belgium) on a population level. The odds ratios 
for the presence of the risk allele in individuals from the general population were lower in 
comparison to those of heavy drinkers without liver disease PNPLA3 (ORpop = 1.66 [1.49 -
1.83] vs. ORalc = 2.21 [1.98 - 2.43]), TM6SF2 (ORpop = 1.48 [1.24 - 1.72] vs. ORalc = 1.63 
[1.47 - 1.80]) and MBOAT7 (ORpop = 1.19 [1.10 - 1.30] vs. ORalc = 1.35 [1.26 - 1.44]) (Figure 
2). Population Attributable Risks (PAR) were calculated against population controls and 
controls drinking harmfully but free of liver injury (Supplementary Table 5). The PAR% in 
individuals drinking harmfully ranged from 20.6% to 27.3% for PNPLA3; 2.5 % to 5.2 % for 
TM6SF2; and 7.4 % to 17.2 % for MBOAT7 (Supplementary Table 5). 
 
The strongest signal at the MBOAT7 locus was obtained for the imputed variant rs626283 (P 
= 1.07 × 10−5; OR = 1.36 [1.19 - 1.57]). The results from the meta-analysis (Figure 3) 
identified a cluster of variants in high linkage disequilibrium (LD) covering the 5’ region of 
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the neighbouring TMC4 and MBOAT7 genes. Fine mapping genotyping and conditional 
analysis using a total of 13 SNPs from the region confirmed the principal location of the 
association signal (Supplementary Table 6). The top variant identified through fine mapping, 
rs641738 is in high LD with rs626283 (r2 = 0.98). The strongest signal at the TM6SF2 locus 
was obtained in the validation cohort for variant rs58542926 (P = 7.34 x 10−5, OR = 1.59 
[1.26 - 1.99]) which is in complete LD with SUGP1 rs10401969 (Table 2) (Supplementary 
Figure 4). 
Cis quantitative trait locus expression (cis-eQTL) analyses were performed for MBOAT7 
using the genomic intervals displayed in Figure 3 and publicly available human liver 
datasets14. The MBOAT7 and TMC4 transcripts are both expressed in human liver 
(Supplementary Figure 5). Variant rs641738 showed strong association with expression of 
MBOAT7 in the two datasets14 (Pexpression = 1.17 × 10−13 and Pexpression = 2.23 × 10−3).  For this 
variant, significant genotype-specific differential expression for the disease-associated allele 
was observed in liver tissue from patients with alcohol-related cirrhosis for MBOAT7 but not 
for the neighbouring TMC4 gene (Supplementary Figure 6).  
 
This first genome-wide genetic assessment for alcohol-related cirrhosis confirms the 
prominent role of PNPLA3 – a gene identified first in a previous candidate gene association 
study9 and confirmed in recent meta-analyses26,39 – but also identified two novel loci of 
genome-wide significance which significantly influence risk, MBOAT7 and TM6SF2. 
Associations persist after adjustment for gender, age, BMI and type 2 diabetes in a subset of 
patients (64%) in whom complete phenotype information was available. The observed 
unadjusted odds ratios for all three loci were similar to those corrected for potential 
confounder variables supporting their relevance as risk loci for the development of alcohol-
related cirrhosis. However, if the primary replication measure were a fully adjusted analysis 
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then TM6SF2 would have associated with a nominal p-value of 0.020 and so would not have 
met Bonferroni-corrected significance. 
Other liver-related phenotypes including NAFLD7,15, chronic hepatitis C16, gallstone 
disease17, primary biliary cirrhosis18, primary sclerosing cholangitis19 and drug-induced liver 
injury 20 have been investigated on a genome-wide scale.-The delay in the systematic 
investigation of alcohol-related cirrhosis is somewhat surprising. It may in part be due to the 
difficulties encountered in recruiting appropriate controls – namely individuals exposed to 
sufficient amounts of alcohol but without evidence of significant alcohol-related liver injury. 
Very few studies have chosen such approach8,9. The importance of using long term heavy 
drinkers as controls is underlined by the lower odds ratios for all three loci when analysed 
against the general population controls (Figure 2). To recruit appropriate controls exposed to 
alcohol but without alcohol-related cirrhosis, we established a collaboration of hepatology and 
psychiatry centres where relevant dataset were available. In the current study the alcohol-
related cirrhosis risk loci are clearly distinct from the reported loci for alcohol dependence, 
consumption, and withdrawal symptoms12,21–24. Further, in candidate gene studies of alcohol 
dehydrogenase 1B (ADH1B), aldehyde dehydrogenase 2 (ALDH2) and GABRA2, no evidence 
of association with alcohol-related liver disease was found25  suggesting that the genetic risk 
for alcohol dependence and alcohol-related injury are distinct. 
Genetic variation at PNPLA3 has been established as a risk factor for alcohol-related cirrhosis 
in previous studies8,9 and meta-analyses26,39. The functional significance of the non-
synonymous variant rs738409 has been explored10,11,27, and data from the present study 
underline its importance on a genome-wide level. 
One of the other top-hits identified in this study, rs641738, locates in the region 19q13.42 and 
contains the TMC4 and MBOAT7 genes. Analysis of eQTL data sets indicates that the lead 
variant alters the expression of the MBOAT7 gene14, and that this variant is associated with 
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genotype-specific expression in liver tissue from patients with alcohol-related cirrhosis 
(Supplementary Figure 6). These data implicate rs641738 as the functional variant influencing 
the expression of MBOAT7 and influencing alcohol-related cirrhosis risk. MBOAT7 encodes 
an enzyme with lysophosphatidylinositol acyltransferase activity and has been implicated in 
anti-inflammatory processes through regulating arachidonic acid levels in neutrophils28. In rat 
liver microsomes, MBOAT7 catalyses the transfer of fatty acid between phospholipids and 
lysophospholipids29, a potent driver mechanism of hepatic inflammation. A key molecular 
product of this enzymatic reaction is sensed by GPR5530, a lysophosphatidylinositol receptor 
with cannabinoid sensitivity; this therefore, provides a  link between MBOAT7 and the known 
role of the endocannabinoid system in hepatic extracellular matrix remodelling31,32. These 
functional observations provide a hypothetical mechanism through which this identified 
variant may modulate inflammation-driven liver fibrogenesis in alcohol-related steatosis.  
The final top-hit identified in the present study, rs58542926 is a coding variant (E167K) in 
TM6SF2, a reported locus for NAFLD phenotypes15,33, and a protective factor against 
cardiovascular disease40. At a functional level TM6SF2 activity is required for very low 
density lipoprotein (VLDL) secretion, and the identified variant might result in impaired 
biological function causing hepatic lipid trapping and, thus, steatosis15. PNPLA3 as well as 
TM6SF2 contain functional variants which associate with both alcohol-related and obesity-
related liver disease, demonstrating a striking similarity in their heritability, which echo the 
other similarities in their clinical presentation and histopathology. 
A previous GWAS in NAFLD identified a significant association between liver histology and  
a variant in the neurocan (NCAN) gene34, but later validation in two subsequent GWAS 
demonstrated that the associations linked to variants within the neighboring TM6SF2 gene 
rather than NCAN15,33. A recent candidate gene study from our group found an association 
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between the NCAN rs2228603 variant and hepatocellular carcinoma41, but not with cirrhosis 
per se, most likely because this is not the true risk variant for cirrhosis. 
In conclusion, the present study confirms PNPLA3 as a risk locus for alcohol-related cirrhosis 
and identifies TM6SF2 and MBOAT7 as additional risk loci. All three genes are functionally 
annotated as being involved in lipid metabolic processes. It is known that variants in both 
PNPLA3 and TM6SF2 are associated with increases in intrahepatic fat compatible with loss of 
function mutations leading to lipid trapping within hepatocytes10. Thus, it can be hypothesized 
that these genetic variants confer risk via dysfunctional lipid turnover. Whether the fine 
mapping studies identified the variants that exert the functional variability of the coded 
protein crucial for liver phenotypes requires further in depth research. The top hits overlap 
with those identified as risk factors for NAFLD implying that both conditions share 
mechanisms of pathogenesis and that the risk genes may be therapeutic targets in both 
disorders. Also, the variants at the three identified loci may help to define high risk 
populations for targeted abstinence intervention and hepatic surveillance programmes35,36. 
 
Data access: The metanalysis results for all imputed variants and further information are 
available at http://gengastro.med.tu-dresden.de/suppl/alc_cirrhosis/. Individual-level data are 
available from the authors upon request. 
 
URL section 
The software IMPUTE, SNPTEST and META is accessible under url: 
http://www.stats.ox.ac.uk/~marchini/software/gwas/gwas.html. BEAGLECALL is accessible 
under url: http://faculty.washington.edu/browning/beaglecall/beaglecall.html. 
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TABLES 
Table 1: Overview of the study populations included in the discovery and validation cohorts and the population controls  
Variable 
Discovery 
** Validation ** Non-alcoholic population controls 
Germany 
GWAS 1 (n=1,490) 
United Kingdom 
GWAS 2 (n=648) 
Germany 
(n=1,290) 
Belgium 
(n=780) 
Germany 
 
United 
Kingdom 
Belgium 
 
Cases 
(n=410) 
Controls 
(n=1,080) 
 Cases 
(n=302) 
Controls 
(n=346) 
Cases 
(n=529) 
Controls 
(n=761) 
Cases 
(n=619) 
Controls 
(n=161) (n=736) (n=763) (n=658) 
Age* 
(years)  
53  
(47-61) 
42  
(36-48) 
53  
(47-60) 
49  
(42-56) 
54  
(47-62) 
46  
(39-53) 
55  
(49-61) 
47 ( 
41-55) 
64  
(57-68) 
37  
(28-50) 
51  
(38-61) 
Gender  
(% male) 
71 100 68 77 72 83 70 69 50 39 44 
BMI*+  
 
26.2  
(22.8-29.3) 
24.8 
 (22.7-7.5) 
24.8 
 (22.8-
6.8) 
24.6  
(22.8-
26.6) 
26.0  
(23.0-
29.2) 
24.3 
(21.7-
27.0) 
25.8  
(22.7-9.8) 
22.8  
(20.6-5.7) 
25.9  
(23.6-8.4) 
N/A 25.2 
 (22.3-8.4) 
Diabetes Type II + 
(%) 
24 4.0 0^ 0^ 18.1 11.3 18.2 2 9.5 N/A 5.4 
*All quantitative measures are median (interquartile range); N/A: not available 
**Cases and controls were assigned to groups as detailed in the text and Supplementary Methods.  
+ Phenotypic information was available for BMI/Type 2 diabetes as follows:  
German discovery cohorts: cases 71 % / 97 %; controls 70 % / 74 %; UK discovery cohorts: cases 80 % / 100 %: controls 53 % / 100 %  
German replication cohorts: cases 50 % / 76 %; controls 40 % / 64 %; Belgian replication: cases 85 % / 93 %; controls 91 % / 99 %  
^ Individuals with type 2 diabetes and/or BMI >28 were excluded from the UK collections a priori 
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Table 2: Association results for lead markers of regions entering the validation stage of the GWAS. 
 Discovery Validation Combined* 
SNPs Locus Chr SNP id Ref. 
allele 
Ref. 
af 
Meta P 
value+ 
Germany/UK 
I2
*+ 
OR [95% CI]  
 
Meta P value 
Germany/Belgiu
m 
I2 OR [CI 95] 
 
Meta P value OR [95% CI] 
 
SNP 1 PNPLA3 22 rs738409 G 0.27 1.17 × 10-28 6
0 
2.39 [2.05-2.78] 4.59 × 10-22 1
7 
2.03 [1.76-2.35] 1.54 × 10-48 2.190 [1.97-2.43] 
SNP 2 TM6SF2** 19 rs10401969 C 0.08 7.81 × 10-7 0 1.92 [1.48-2.50] 1.24 × 10-4 0 1.57 [1.25-1.97] 7.89 × 10-10 1.715 [1.44-2.04] 
  19 rs58542926 T 0.08 2.86 × 10-6 0 1.87 [1.44-2.43] 7.34 × 10-5 0 1.59 [1.26-1.99] 1.33 × 10-9 1.704 [1.43-2.02] 
SNP 3 TM4SF20 2 rs62190923 G 0.21 1.31 × 10-6 0 0.64 [0.54-0.77] 0.73 0 1.03 [0.87-1.22] - - 
SNP 4 INTERGENIC 8 rs7812374 T 0.58 1.46 × 10-6 0 0.70 [0.60-0.81] 0.69 69 0.97 [0.85-1.11] - - 
SNP 5 DUSP1 5 rs6556045 A 0.06 2.51 × 10-6 0 2.11 [1.55-2.87] 0.16 87 1.20 [0.93-1.56] - - 
SNP 6 LPHN2 1 rs6605237 T 0.27 5.43 × 10-6 0 1.46 [1.24-1.71] 0.80 0 0.98 [0.84-1.14] - - 
SNP 7 IL21 4 rs17886348 T 0.08 7.64 × 10-6 60 1.79 [1.39-2.31] 0.99 0 1.00 [0.77-1.30] - - 
SNP 8 PDE7B 6 rs7769670 A 0.14 7.84 × 10-6 0 1.58 [1.29-1.93] 0.37 0 1.09 [0.90-1.33] - - 
SNP 9 INTERGENIC 8 rs7845021 C 0.61 1.02 × 10-5 0 0.73 [0.64-0.84] 0.19 0 1.09 [0.95-1.26] - - 
SNP 10 MBOAT7 19 rs626283 C 0.44 1.07 × 10-5 0 1.36 [1.19-1.57] 2.29 × 10-5 0 1.33 [1.17-1.53] 1.03 × 10-9 1.349 [1.23-1.49] 
* The results of the combined analyses are only provided for variants meeting a Bonferroni corrected p<0.05 at the validation stage.  
** The lead SNP rs739846 failed Taqman genotyping for technical reasons, rs10401969 was used as a replacement (r2=1.0, Pmeta rs739846 =7.45 × 10-7) 
The functional variant rs58542926 previously reported at the TM6SF2 locus is included 25, 44 
+ Significance derived from a fixed effect meta-analysis; ++ I2-measure of percentage of between cohort heterogeneity37. 
Abbreviations: SNP-single nucleotide polymorphism SNP-id SNP identification number; Chr: chromosome; Ref allele---reference allele; Ref af---
frequency of the reference allele 
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Table 3: Validation analysis of the replicated loci in the primary analysis  
adjusted for sex, age, BMI and type 2 diabetes, by gender  
* Odds ratios provided with 95 % Confidence Intervals in square brackets  ** The unadjusted Odds Ratios are provided for comparison. 
Abbreviations: Chr: chromosome; SNP-id single nucleotide polymorphism identification number 
Locus Chr SNP id 
 
Unadjusted Odds Ratio* 
(p-value) 
 
Adjusted Odds Ratio 
(p-value) 
Gender-specific analysis: Odds Ratios 
Adjusted,  
men only 
Adjusted 
women only  
Unadjusted** 
men only 
Unadjusted ** 
women only  
PNPLA3 22 rs738409 2.03 [1.76-2.35] 
4.59 × 10-22 
2.12 [1.73-2.59]  
4.05 × 10-13 
2.07[1.63-2.63] 2.69[1.79-4.04] 2.07[1.73-2.47] 2.44[1.79-3.31] 
TM6SF2 
19 rs10401969  1.57 [1.25-1.97] 
1.24 × 10-4 
1.43[1.06-1.94]  
0.020 
1.42[0.98-2.05] 1.47[0.78-2.78] 1.51[1.14-1.98] 1.67[1.04-2.68] 
19 rs58542926 1.59 [1.26-1.99] 
7.34 × 10-5 
1.43[1.05-1.94]  
0.022 
1.44[0.99-2.09] 1.41[0.76-2.62] 1.53[1.16-2.02] 1.64[1.03-2.61] 
MBOAT7 
19 rs626283 1.33 [1.17-1.53] 
2.29 × 10-5 
1.41[1.17-1.70]  
3.81 × 10-4 
1.19[0.95-1.49] 2.21[1.52-3.21] 1.27[1.08-1.49] 1.51[1.16-1.96] 
19 rs641738 1.35 [1.18-1.54] 
1.30 × 10-5 
1.43[1.18-1.72] 
2.11 × 10-4 
1.22[0.98-1.52] 2.21[1.52-3.22] 1.29[1.10-1.51] 1.52[1.17-1.98] 
FIGURE LEGENDS 
Figure 1 
Genome-wide association meta-analysis of 712 cases with alcohol-related cirrhosis and 1,466 
controls. P values are shown for SNPs that passed quality control. The genome-wide 
significance threshold (P = 5 × 10-8) is indicated as a red line. The threshold for replication 
follow-up (P= 2.5 × 10-5) is indicated as a black line. Nearest genes are annotated for each 
locus, although the causal variants are not unequivocally known with the exception of 
PNPLA3. SNP, single nucleotide polymorphism. 
 
Figure 2 
Forest plots of odds ratios of the susceptibility loci for alcohol-related cirrhosis in comparison 
to alcohol misusers and population controls. Data generated using the rmeta package in R. 
 
Figure 3 
Fine-mapping analysis of the MBOAT7 association signals. The –log10 of p values are plotted 
against the SNP genomic position based on NCBI build 37. The squares denote genotyped 
SNPs; the circles imputed SNPs (using 1,000 Genomes Project–based imputation). SNPs are 
coloured to reflect correlation with the most significant SNP with red denoting the highest LD 
(r2 > 0.8) to the lead SNP. Estimated recombination rates from 1,000 Genomes Project 
(hg19/genomes Mar2012 EUR) are plotted in blue to reflect the local linkage disequilibrium 
structure. Gene annotations are obtained from the UCSC genome browser. Data generated 
using LocusZoom 38. SNP, single nucleotide polymorphism; LD, linkage disequilibrium. 
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ONLINE METHODS 
Phenotyping of cases and controls 
Across all samples, cases were defined as patients with clinically diagnosed or biopsy-proven 
cirrhosis48 on a background of past and/or present alcohol consumption of at least 60 g/day 
for women and 80 g/day for men for more than 10 years after exclusion of other causes of 
cirrhosis. Control individuals had no clinical or laboratory evidence of liver disease, 
confirmed by non-invasive assessment of liver fibrosis or examination of liver histology, on a 
background of alcohol dependence (per DSM-IV criteria) or reported alcohol consumption 
according to the criteria noted above. Case and control cohorts and details of recruitment 
protocols were reported previously for the German 9,23,41, UK 42 and Belgian 51 cohorts. 
Germany, Austria and Switzerland 
German/Austrian/Swiss patients comprised alcoholics with a long-term history of chronic 
alcohol abuse. Cases with alcoholic cirrhosis were recruited from gastroenterology and 
hepatology departments of the university hospitals in Dresden, Bonn, Leipzig, Kiel, 
Regensburg and Frankfurt (all Germany), Salzburg (Austria) and Bern (Switzerland). Control 
subjects drinking excessively, but without alcoholic liver cirrhosis, were recruited at 
psychiatry centres specialized in addiction medicine in Regensburg, Munich and Mannheim 
(all Germany), and Meiringen (Switzerland). Recruitment details were reported previously 
both for aspects related to liver disease 9 and those related to psychiatry 12. Patients were 
recruited between 2000 and 2014 according to the same criteria across centres. Past and 
present alcohol consumption was quantified through interrogation during a face-to-face 
interview. All patients from Regensburg, Mannheim and Meiringen received a diagnosis of 
alcohol dependence (per DSM-IV criteria) by the consensus of 2 clinical psychiatrists. All 
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patients underwent careful clinical examination, standard laboratory testing and abdominal 
ultrasound. Chronic viral hepatitis was excluded in all patients by testing for hepatitis B 
surface antigen, anti-HBc and third-generation hepatitis C antibody ELISA. Serum levels of 
ferritin and transferrin saturation were determined to rule out hereditary hemochromatosis, 
and neither clinical nor serological signs of autoimmune liver disease were present. All 
patients and controls were of self-reported German ancestry. 
Patients were defined as cases (alcoholic cirrhosis) when the presence of cirrhosis was 
assumed by at least one of the following criteria: 1. presence of cirrhosis as per liver biopsy 
(fibrosis stage 5 or 6 according to Ishak et al. 44) or 2. unequivocal clinical and laboratory 
evidence for the presence of cirrhosis as reflected by a combination of (a) abnormal standard 
“liver” blood tests (transaminases, gamma-glutamyl-transpeptidase, coagulation tests, serum 
albumin concentration, platelet count), (b) cirrhosis-related complications including 
encephalopathy or ascites, (c) sonographic and/or radiological (computed tomography) 
findings suggestive of cirrhosis (hunched liver surface, ascites, splenomegaly), and (d) 
detection of esophageal varices via upper gastrointestinal endoscopy.  
Corresponding control subjects were defined as alcoholic patients without cirrhosis when 
none of the criteria set forth for case patients were present. Patients gave written, informed 
consent and the study received approval from the ethics committees of all participating 
centres. 
Belgium 
Heavy drinkers with alcoholic cirrhosis (cases) and alcoholics without significant fibrosis 
(controls) with a history of excessive alcohol intake of ≥ 60 g/day (> 77 % drank more than 
80 g/day) were recruited between 2002 and 2014 in Brussels and Haine-Saint-Paul (both 
Belgium). Cases were characterized as described above for the German/Austrian/Swiss 
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cohort. All heavy drinkers without clinically evident cirrhosis received a diagnosis of alcohol 
dependence based on DSM-IV criteria. They were screened with transient elastography 
(Fibroscan®) for the measure of liver stiffness (LSM) and/or liver biopsy to rule out 
significant liver fibrosis or cirrhosis related to excessive alcohol intake. Patients with a 
median LSM < 7 kPa were considered as having no or mild fibrosis 45. In addition, 660 
healthy Caucasians individuals from the general population were recruited at the same centres 
in Belgium. These individuals were recruited before minor surgery procedure or routine 
colonoscopy. They had neither clinical nor biochemical evidence (routine blood screening) of 
liver disease, nor evidence of other major pathological conditions. Written informed consent 
was obtained from all included subjects and the study received ethical approval. 
United Kingdom 
Subjects with self-reported English, Scottish, Welsh or Irish descent were recruited from the 
Centre for Hepatology at the Royal Free Hospital, London. Criteria applied for dissecting 
cases from control subjects were the same as outlined for the German/Austrian/Swiss cohort. 
The protocol was approved by the institutional review board and all included subjects 
consented to inclusion into the study. 
Genotyping, quality control and GWAS 
Genomic DNA was extracted from peripheral blood samples according to standard procedures 
and quantified using the PicoGreen dsDNA Quantitation Kit (Invitrogen Corporation, 
Carlsbad, California) and normalized to 50 ng/μL. Genotyping on Illumina bead chip arrays 
was performed according to the manufactures instructions and as reported before23. The first 
GWAS included 410 Germans with alcohol-related cirrhosis genotyped on the OmniExpress 
array (Version 12v1_j, Illumina Inc., San Diego, CA, USA) and 1,119 heavy drinkers without 
liver disease from a German psychiatric consortium  genotyped on Illumina HumanHap550 
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BeadChip (N=407), Illumina Human610Quad (N=329) and Illumina Human660w Quad 
BeadChip arrays (N=383). In the second GWAS, 302 cases and 346 controls from the United 
Kingdom were genotyped using OmniExpress (version 24v1-0_a). To harmonize the German 
data sets, genotype probabilities were generated from signal intensity data from each array 
employing a Hidden Markov model of haplotype frequencies using BEAGLECALL48 for all 
samples in a single computational batch. The genomic inflation factor λ calculated on the 
quality filtered dataset improved from 1.187 before to 1.1446 after BEAGLECALL for the 
German data set. We used EIGENSTRAT 49 to calculate principal components of genetic 
variation in the German genotype data. After correction for the first principal component the λ 
decreased 1.019 for the German case-control data set. Posterior genotype probabilities were 
converted to PLINK format hard calls using fcGENE 50 for initial quality control steps. 
Individuals with genotyping success < 97%, outlying autosomal heterozygosity (mean + 3*sd, 
mean-3*sd), kinship coefficient (𝜋𝜋�) < 0.185 and those failing gender check were excluded 
from analysis. Samples that clustered outside the CEU HapMap population using 
multidimensional scaling (MDS) were likewise excluded. MDS analysis was performed on a 
cleaned LD pruned data set (indep-pairwise; excluding HLA region chr6:28477797-
33448354; minor allele frequency >0.01, HWE P >1 × 10-6, genotyping rate threshold for 
each marker > 95 %, genotyping rate threshold for each individual > 95 %) that was merged 
with Hapmap Phase III data from 11 different populations. Individuals deviating more than 
3sd from the median European MDS cluster were excluded as population outliers. All QC 
filtering for the German and UK data sets was performed using PLINK (v1.07).  
Imputation and GWAS metaanalysis in German and UK patients 
To harmonize the four German GWAS data sets we selected only those SNPs that were 
genotyped on all arrays (N=298,405 quality controlled SNPs, intersection) as input for further 
imputation steps. Genotypes were imputed without pre-phasing to improve accuracy. Sample 
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phasing and genotype imputation was performed using IMPUTE 2 to reference 1000 
Genomes Phase 3 (October 2014 release) or Phase 1 (March 2012 release) for X chromosome. 
For the German data set posterior genotype probabilities obtained by BEAGLECALL were 
used as input for IMPUTE v2.3.1. We controlled for between array differences among control 
samples genotyped on HumanHap550, Illumina Human610Quad and Illumina Human660w 
Quad by subsequently assigning alternating case control status to all samples on one array. 
We then performed case-control association analysis between arrays for all markers that are 
present on all three genotyping arrays to identify potential platform genotyping differences. 
All markers with p < 0.001 between all combination of control array pairs were identified as 
potential source of genotyping incongruities as recommended (“Method 3”) by Sinnott and 
Kraft 2012.46 These markers were excluded from further analysis. We also excluded markers 
with a HWE deviation of P < 10−6 in the combined control sample set. 
Post-imputation quality filtering was performed using a minimum impute info score of 0.8,  a 
Hardy-Weinberg equilibrium 1 × 10-6, a minor allele frequency > 1%, yielding 6,866,424 
SNPs for the German data set and 7,871,013 SNPs for the UK data set for further analysis. 
Quality controls and phenotypic association analysis on this marker set was performed with 
SNPTEST (v2.5) 47, using score statistic under an additive allelic effect model, including 
gender, age, BMI and type 2 diabetes status as covariates in the adjusted analyses.  
Study-specific β - estimates from the German and UK scans were genomic-control adjusted 
prior to a fixed-effect model meta-analysis using an inverse variance weighted method 
implemented in META 22. Meta-analysis was restricted to markers present in both data sets 
(N=6,770,425). The λ value was 1.005 for the combined meta-analysis.  
At stage II the SNPs were validated in independent samples from Germany (N=1,290) and 
Belgium (N=779). Study-specific β – estimates and standard errors were derived from the 
German and Belgium stage II samples under an additive allelic effect model using PLINK 
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(v1.07) and further analysed using a fixed-effect model meta-analysis. Cochrane's Q and I 
square statistics were employed to assess consistency of effect and to quantify heterogeneity 
between both sample sets. 
Validation Genotyping 
One microliter of genomic DNA was amplified with the GenomiPhi (Amersham, Uppsala, 
Sweden) whole genome amplification kit and fragmented at 99°C for three minutes. 
Genotyping of SNPs rs738409 (hcv7241), rs4823173 (hcv25931728), rs10401969 
(hcv30444981), rs58542926 (hcv89463510), rs6556045 (hcv29201253), rs6605237 
(hcv27032502), rs17886348 (hcv25618641), rs7769670 (hcv29432279), rs7845021 
(hcv1383849), rs626283 (hcv2916337), rs8736 (hcv2916339), rs641738 (hcv8716820), 
rs62190923 (Assay by Design), rs7812374(AdD), rs34564463(AdD), rs739846(AdD(failed)) 
was performed using the Taqman chemistry (Applied Biosystems, Foster City, Ca, USA) on 
an automated platform. Reactions were completed and read in a 7900 HT TaqMan sequence 
detector system (Applied Biosystems). The amplification reaction was carried out with the 
TaqMan universal master mix. Thermal cycling conditions consisted of 1 cycle for 10 
minutes at 95°C, 45 cycles for 15 seconds at 95°C, and 45 cycles for 1 minute at 60°C. 
Genotyping of SNPs rs709186, rs9874300, rs5867471, rs71313753, rs2531812, rs16849557, 
rs1177809, rs1560408, rs6846459, rs36640, rs254283, rs8112480, rs58694079, rs4806498, 
rs10416555, rs1050527, rs626283, rs36654, rs36633, rs79199039, rs2576452, rs73062690 
was performed using the Sequenom iPLEX Gold chemistry MassARRAY platform. All 
process data were logged and administered with a database-driven LIMS 18.  
Software and statistical analysis 
BEAGLECALL (1.0.1) was used for genotype calling of the German data set. SNP 
imputation was performed with IMPUTE v2.3.1. QC filtering was performed using PLINK 
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(1.07) and on BEAGLE and SNPTEST output data. Processing and transformation of SNP 
data was accomplished by using fcGENE (1.0.7). Stage I association tests were performed 
by SNPTEST (2.5), stage II logistic regression tests were performed using PLINK (1.07). The 
program META (1.6.0) was used for meta-analysis of stage I, II and combined data sets.  
Forest plots were generated using rmeta package in R. Regional fine mapping plots were 
generated using LocusZoom (1.1)38. Population attributable risk (PAR) was calculated as 
PAR=PRF×(RR-1)/1+PRF×(RR-1). The Population Attributable Risk percentage (PAR%) was 
calculated as PAR=PRF×(RR-1)/1+PRF×(RR-1)×100% where PRF is the population prevalence 
of the risk factor in alcohol misusers or in the general population for all three analyzed 
populations, respectively. The allelic odds ratio was used as an approximation for the estimate 
relative risk (RR) of disease due to exposure of the risk allele. Combined PAR was calculated 
by the formula PARcombined = 1-(1-PAR1)×(1-PAR2)×(1-PAR3). 
Expression analysis of MBOAT7 and TMC4 transcripts 
The qRT was performed using specific primer for TMC4 and MBOAT7 and normalized to 
ACTB in cDNA from patients with alcoholic liver cirrhosis bearing the homozygous ancient, 
heterozygous and  homozygous mutant genotype for rs641738 (CC n=5; CT n=6, TT n=6). 
Primer sequences are provided in Supplementary Table 7. 
 
